Complicated intra-abdominal infections: Pathogens, resistance: Recommendations of the Infectliga on antbiotic therapy;Komplizierte intraabdominelle Infektionen: Erreger, Resistenzen: Empfehlungen der Infektliga zur Antibiotikatherapie

Chirurg

Volumn 81, Issue 1, 2010, Pages 38-49

  Bodmann, K F ^a  

^a Werner Forssmann Hospital   (Germany)

Author keywords

Antimicrobial treatment; Intra abdominal infections; Pathogens; Resistance; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT;

ABDOMINAL ABSCESS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL TRANSLOCATION; CROSS INFECTION; DOSE RESPONSE; DRUG COMBINATION; HUMAN; INTESTINE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PERITONITIS;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL TRANSLOCATION; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; INTESTINES; MICROBIAL SENSITIVITY TESTS; PERITONITIS;

EID: 74349094914     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-009-1822-9     Document Type: Article

References (63)

1. Adam D, Dörr HW, Link H, Lode H (eds) (2004) Die Infektiologie. Springer, Berlin Heidelberg New York, S 33.
2. Angeras MH, Darle N, Hamnström K et al (1996) A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 28: 513-518.
3. Babinchak T, Ellis-Grosse E, Dartois N et al (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical data. Clin Infect Dis 41: 354-366.
4. Bare M, Castellis X, Garcia A et al (2002) Excess mortality associated with inappropriate initial empiric antibiotic therapy in patients undergoing surgery for intra-abdominal infection. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, O224.
5. Barie PS, Vogel SB, Dellinger EP et al. (1997) for the Cefepime Intra-abdominal Infection Study Group. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Ann Surg 132: 1294-1302.
6. Barie PS, Hydo LJ, Shou J et al (2005) Influence of antibiotic therapy on mortality of critical surgical illness caused or complicated by infection. Surg Infect 6(1): 41-54.
7. Burnett RJ, Haverstock DC, Dellinger EP et al (1995) Definition of the role of enterococcus in intra-abdominal infection: analysis of a prospective randomized trial. Surg Infect 118: 716-723.
8. Cattan P, Yin DD, Sarfati E et al (2002) Cost of care for patients with community acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 21(11): 787-793.
9. Cohn SM, Lipsett PA, Buchmann PG et al (2000) Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections. Ann Surg 232: 254-262.
10. Dupont H (2007) The empiric treatment of nosocomial intra-abdominal infections. Int J Infect Dis 11 [Suppl 1]: 1-6.
11. Durst J, Rohen JW (2007) Bauchchirurgie. 2. Aufl. Schattauer, Stuttgart.
12. Ess S, Yin D, Lyu R et al (2002) Outcomes of initial empiric antibiotic therapy and hospital resource use in patients undergoing surgery for community-acquired intra-abdominal infections in three Swiss hospitals. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, O226.
13. Gastmeier P, Sohr D, Geffers C et al (2005) Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS). Infection 33(2): 50-55.
14. Gonzenbach HR (1987) Die Behandlung intraabdomineller Infektionen mit Beta-Laktam-Antibiotika. Resultate einiger kontrollierter, prospektiver Studien. Infection 15: 179-182.
15. Hau T (2002) Antibiotic treatment of intra-abdominal infections. Intensive Notfallbehandl 27(1): 16-22.
16. Huizinga WK, Warren BL, Baker LW et al (1995) Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 36 [Suppl A]: 179-189.
17. Jaccard C, Troillet N, Harbard S et al (1998) Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42: 2966-2972.
18. Kaye KS, Engemann JJ, Fraimow HS et al (2004) Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management. Infect Clin Dis N Am 18: 467-511.
19. Kresken M (2008) Highlights der PEG-Resistenzstudie 2007. J Chemother 5: 232.
20. Kresken M, Leitner E, Seifert H et al (2008) Empfindlichkeit klinischer Isolate häufig vorkommender Bakterienspezies gegenüber Tigecyclin. J Chemother 5: 205-226.
21. Krobot K, Yin D, Zhang Q et al (2004) Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis 23: 682-687.
22. Kujath P, Hoffmann M, Rodloff A (2008) Antibiotika- und Pilztherapie bei intraabdominellen Infektionen. Chirurg 79: 295-305.
23. Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589-1596.
24. Livermore DM (2005) Minimising antibiotic resistance. Lancet Infect Dis 5: 450-459.
25. Lucasti C, Jasovich A, Umeh O et al (2008) Efficacy and tolerability of iv doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind noninferiority study. Clin Ther 30(5): 868-883.
26. Marangoni M, Song J, Herrington J et al (2006) Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 244(2): 204-211.
27. Marshall JC (2004) Intra-abdominal infections. Microbes Infect 6: 1015-1025.
28. Mazuski JE, Sawyer RG, Nathens AB et al (2002) The Surgical Infection Society guidelines on antimicrobial therapy for intraabdominal infections: an executive summary. Surg Infect 3: 161-173.
29. Mazuski JE (2005) Clinical Challenges and Unmet Needs in the Management of Complicated Intra-Abdominal Infections. Surg Infect 6 [Suppl 2]: 49-69.
30. Mazuski JE (2007) Antimicrobial treatment for intra-abdominal infections. Expert Opin Pharmacother 8(17): 2933-2945.
31. Mazuski JE, Solomkin JS (2009) Intra-abdominal infections. Surg Clin North Am 898: 421-429.
32. Methar S, Dewar EP, Leaper DJ et al (1997) A multicenter study to compare meropenem and cefotaxime and metronidazole in treatment of hospitalized patients with serious infections. J Antimicrob Chemother 39: 631-638.
33. Mosdell DM, Morris DM, Voltura A et al (1991) Antibiotic treatment for surgical peritonitis. Ann Surg 214: 543-549.
34. Nathans AB, Rotstein OD, Marshall JC (1998) Tertiary Peritonitis: Clinical Features of a Complex Nosocomial Infection. World J Surg 22: 158-163.
35. Nyström PO, Bax R, Dellinger EP et al (1990) Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. World J Surg 14: 148-158.
36. Paterson DL (2004) Collateral damage from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38 [Suppl 4]: 341-345.
37. Pieracci FM, Barie PS (2007) Intra-abdominal infections. Curr Opin Crit Care 13: 440-449.
38. Potoski BA (2006) Evaluation of the guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Ashp Midyear Clinical Meeting 42: p pi-223.
39. Rapp RP (2000) Overview of resistant gram-positive pathogens in the surgical patient. Surg Infect 1(1): 39-47.
40. Raymond DP et al (2002) Preventing antimicrobial-resistant bacterial infections in surgical patients (CDC/SIS position paper). Surg Infect 3(4): 375-378.
41. Rodloff A, Leclercq R, Debbia EA et al (2008) Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and UK as part of the tigecycline evaluation and surveillance trail. Clin Microbiol Infect 14: 307-314.
42. Roehrborn A, Thomas L, Potrech O et al (2001) The microbiology of postoperative peritonitis. Clin Infect Dis 33: 1513-1519.
43. Sandiumenge A, Diaz E, Rodriguez A (2006) Impact of diversity of antimicrobial use on the development of antimicrobial resistance. J Antimicrob Chemother 57: 1197-1204.
44. Schäfer V, Hunfeld KP (2004) Ambulant erworbene, polymikrobielle Infektionen. Thieme, Stuttgart.
45. Seguin P, Lavoille B, Chanavaz C et al (2006) Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 12: 980-985.
46. Seifert H, Leitner E, Körber-Irrgang B et al (2008) Comparative in vitro activity of tigecycline against clinical isolates of the Acinetobacter baumannii group: results of the German TEST (G-TEST) surveillance program 2005-2007. 48th ICAAC, Washington D. C., Abstract/Poster C2-3870.
47. Sendt W, Altendorf-Hofmann A, Scheele J et al (2002) Association between inappropriate initial empiric antibiotic therapy and the need for re-operation and second-line therapy among German patients undergoing surgery for community acquired intra-abdominal infections. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, O225.
48. Sitges-Serra A, López MJ, Girvent M et al (2002) Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 89: 361-367.
49. Solomkin JS, Mazuski JE, Baron EJ et al (2003) Guidelines for the selection of anti-infective agents for complicated intraabdominal infections. Clin Infect Dis 37: 997-1005.
50. Solomkin JS, Yellin AE, Rotstein OD et al (2003) Ertapenem versus Piperacillin/Tazobactam in the treatment of complicated intraabdominal infections. Results of a double-blind, randomized, comparative trail. Ann Surg 237(2): 235-245.
51. Swenson RM, Lorber B, Michaelson TC (1974) The bacteriology of intra-abdominal infections. Arch Surg 109: 398-399.
52. Töns C (2006) Gastroenterologische Chirurgie, 2. Aufl. Springer, Heidelberg.
53. Vogel F, Bodmann KF u (2004) Expertenkommission der Paul-Ehrlich-Gesellschaft. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. J Chemother 13(2): 46-105.
54. Wacha H, Hau T, Dittmer R, Ohmann C, the Peritonitis Study Group (1999) Risk factors associated with intra-abdominal infections: a prospective multicenter study. Langenbecks Arch Surg 384: 24-32.
55. Wacha H, Warren B, Bassaris H, Nikolaidis P, the Intra-Abdominal Infections Study Group (2006) Comparison of Sequential Intravenous/Oral Ciprofloxacin Plus Metronidazole with Intravenous Ceftriaxone Plus Metronidazole for Treatment of Complicated Intra-Abdominal Infections. Surg Infect 7(4): 341.
56. Walker AP, Nichols RL, Wilson RF et al (1993) Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217: 115-121.
57. Weber SG et al (2003) Fluoroquinolones and the risk for methicillin-resistant staphylococcus aureus in hospitalized patients. Emerg Infect Dis 9: 1415-1422.
58. Weber DJ (2006) Collateral damage and what the future might hold. The need to balance prudent antibiotic utilization and stewardship with effective patient management. Int J Infect Dis 10 [Suppl 2]: 17-24.
59. Werner G (2008) VRE - ein Problem für Deutschland? J Chemother 5: 233.
60. Wilcox MH (2006) Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect 7(1): 69-80.
61. http://www. sepsis-gesellschaft. de Prävalenzstudie des SepNet.
62. http://www. p-e-g. org.
63. earss: European Antimicrobial Resistance Surveillance Study; http://www. rivm. nl/earss/database/.